Compare PAY & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAY | PBLS |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 2021 | 2026 |
| Metric | PAY | PBLS |
|---|---|---|
| Price | $28.02 | $30.83 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $36.29 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 570.4K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.57 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $1,196,507,000.00 | N/A |
| Revenue This Year | $18.60 | N/A |
| Revenue Next Year | $18.89 | N/A |
| P/E Ratio | $178.19 | ★ N/A |
| Revenue Growth | ★ 37.25 | N/A |
| 52 Week Low | $20.11 | $25.56 |
| 52 Week High | $39.38 | $31.51 |
| Indicator | PAY | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 70.42 | 63.88 |
| Support Level | $26.65 | $26.68 |
| Resistance Level | $29.88 | N/A |
| Average True Range (ATR) | 1.16 | 2.34 |
| MACD | 0.89 | 0.29 |
| Stochastic Oscillator | 88.25 | 78.51 |
Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers through a Software-as-a-Service (SaaS), secure, omni-channel technology platform. The platform integrates with a biller's financial and operational systems to provide secure and flexible processing of payments, including credit cards, debit cards, eChecks, and digital wallets, across multiple channels such as online, mobile, IVR, call centers, chatbots, and voice-based assistants. The company generates the majority of its revenue from payment transaction fees processed through its platform. Geographically, it derives the maximum revenue from the United States.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.